98 related articles for article (PubMed ID: 35905642)
21. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
22. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
23. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of Tumor Mutation Burden among Patients with Non-small Cell Lung Cancer Who Received Platinum-based Adjuvant Chemotherapy: An Exploratory Study.
Shen WX; Li GH; Li YJ; Zhang PF; Yu JX; Shang D; Wang QS
J Cancer Prev; 2023 Dec; 28(4):175-184. PubMed ID: 38205359
[TBL] [Abstract][Full Text] [Related]
25. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Kao C; Powers E; Wu Y; Datto MB; Green MF; Strickler JH; Ready NE; Zhang T; Clarke JM
Clin Lung Cancer; 2021 Nov; 22(6):500-509. PubMed ID: 33972172
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
[TBL] [Abstract][Full Text] [Related]
27. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Kim H; Kwon HJ; Kim ES; Kwon S; Suh KJ; Kim SH; Kim YJ; Lee JS; Chung JH
Cancer Res Treat; 2022 Apr; 54(2):424-433. PubMed ID: 34237208
[TBL] [Abstract][Full Text] [Related]
29. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl LM; Hirsch FR; Hwang D; Botling J; Lopez-Rios F; Bubendorf L; Mino-Kenudson M; Roden AC; Beasley MB; Borczuk A; Brambilla E; Chen G; Chou TY; Chung JH; Cooper WA; Dacic S; Lantuejoul S; Jain D; Lin D; Minami Y; Moreira A; Nicholson AG; Noguchi M; Papotti M; Pelosi G; Poleri C; Rekhtman N; Tsao MS; Thunnissen E; Travis W; Yatabe Y; Yoshida A; Daigneault JB; Zehir A; Peters S; Wistuba II; Kerr KM; Longshore JW
J Thorac Oncol; 2020 Sep; 15(9):1409-1424. PubMed ID: 32522712
[TBL] [Abstract][Full Text] [Related]
30. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
31. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
33. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
34. The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer.
Li Y; Ji L; Zhang Y; Zhang J; Reuben A; Zeng H; Huang Q; Wei Q; Tan S; Xia X; Li W; Zhang J; Tian P
MedComm (2020); 2024 Jun; 5(6):e604. PubMed ID: 38840771
[TBL] [Abstract][Full Text] [Related]
35. LRP1B: A Giant Lost in Cancer Translation.
Príncipe C; Dionísio de Sousa IJ; Prazeres H; Soares P; Lima RT
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577535
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Implications of LRP1B and Its Relationship with the Tumor-Infiltrating Immune Cells in Gastric Cancer.
Wang R; Zhang G; Zhu X; Xu Y; Cao N; Li Z; Han C; Qin M; Shen Y; Dong J; Ma F; Zhao A
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136305
[TBL] [Abstract][Full Text] [Related]
37. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
38. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
39. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB
Ramos-Paradas J; Hernández-Prieto S; Lora D; Sanchez E; Rosado A; Caniego-Casas T; Carrizo N; Enguita AB; Muñoz-Jimenez MT; Rodriguez B; Perez-Gonzalez U; Gómez-Sánchez D; Ferrer I; Ponce Aix S; Nuñez Buiza Á; Garrido P; Palacios J; Lopez-Rios F; Garrido-Martin EM; Paz-Ares L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963008
[TBL] [Abstract][Full Text] [Related]
40. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
